Ir para o conteúdo principal

Heron Therapeuti (NASDAQ: HRTX) — Perfil da empresa, notícias e dados financeiros

Logo de Heron Therapeuti
HRTX Heron Therapeuti
Heron Therapeuti primary media
Perfil da empresa

Heron Therapeuti

Heron Therapeutics (NASDAQ:HRTX) specializes in developing innovative treatments aimed at addressing unmet medical needs in pain management and oncology. Their portfolio includes advanced therapeutics designed to improve the lives of patients undergoing surgery or those facing challenging cancer treatments. Heron is dedicated to pushing the boundaries of science to create solutions that can significantly enhance patient care and outcomes. Their objectives focus on advancing their research and development pipeline, ensuring the accessibility of their therapies, and maintaining a strong commitment to ethical practices and sustainability in all their operations.

Resumo

Public USParticipação acionária
1983Ano de fundação
181Funcionários
San Diego, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Heron Therapeuti

  • CINVANTI for chemotherapy-induced nausea and vomiting
  • ZYNRELEF for postoperative pain management
  • SUSTOL for delayed chemotherapy-induced nausea and vomiting
  • HTX-011 for postoperative pain
  • APF530 for chemotherapy-induced nausea and vomiting prevention
  • HTX-034 for postoperative pain management

equipe executiva do Heron Therapeuti

  • Craig Alexander CollardCEO & Director
  • Ira DuarteExecutive VP & CFO
  • Mark E. HensleyExecutive VP & COO
  • William P. ForbesExecutive VP & Chief Development Officer
  • Melissa JarelVice President of Legal
  • Ryan CraigVice President of Marketing
  • John AikenExecutive Director of People Management & Training
  • John C. ArthurSenior Vice President of Manufacturing Development
  • Robert SullivanChief Commercial Officer
  • Brett FleshmanChief Business Officer

Principais indicadores financeiros

Resultados divulgados pela Heron Therapeuti, em USD.

Cap. de mercado
57,2 mi
Receita (TTM)
151,2 mi
P/L
—
LPA (diluído, TTM)
-0.2
Dividend yield
—
Margem de lucro
-22.5%
Receita e lucro anuais da Heron Therapeuti
Fim do ano fiscalReceitaResultado operacionalLucro líquido
154,9 mi-2,5 mi-20,2 mi
144,3 mi-11,5 mi-13,6 mi
127 mi-110,6 mi-110,6 mi
107,7 mi-174,7 mi-134,5 mi